Management of chronic lymphocytic leukemia: An update

Matthew Kaufman, Jian Li Campian, Kanti R. Rai

Research output: Contribution to journalReview articlepeer-review


Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world. It is often discovered on routine blood tests showing the presence of lymphocytosis. CLL has a variable course, with survival ranging from months to many years. In the past several years, discoveries of prognostic markers have helped predict the disease course. In terms of treatment, the emergence of purine analogs and monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52), has significantly changed the landscape of therapeutic options available for CLL.

Original languageEnglish
Pages (from-to)271-278
Number of pages8
JournalCommunity Oncology
Issue number6
StatePublished - Jun 2009


Dive into the research topics of 'Management of chronic lymphocytic leukemia: An update'. Together they form a unique fingerprint.

Cite this